| Identification | Back Directory | [Name]
TC-H 106 | [CAS]
937039-45-7 | [Synonyms]
RGFA 8
TC-H 106
Compound 106
Inhibitor 106
TC-H 106, >98%
Pimelic Diphenylamide 106
Pimelic Diphenylamide 106, >98%
Histone Deacetylase Inhibitor VII
Histone Deacetylase Inhibitor VII, 106
N1-(2-aminophenyl)-N8-p-tolyloctanediamide
N'-(2-aminophenyl)-n-(4-methylphenyl)heptanediamide
RGFA-8; TC-H 106; HISTONE DEACETYLASE INHIBITOR VII
N1-(2-Aminophenyl)-N7-(4-methylphenyl)-heptanediamide
Heptanediamide, N1-(2-aminophenyl)-N7-(4-methylphenyl)-
Histone Deacetylase Inhibitor VII, 106 - CAS 937039-45-7 - Calbiochem | [Molecular Formula]
C20H25N3O2 | [MDL Number]
MFCD17010287 | [MOL File]
937039-45-7.mol | [Molecular Weight]
339.43 |
| Hazard Information | Back Directory | [Description]
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases (HDACs). Unlike the HDAC inhibitor suberoylanilide hydroamic acid, which has a fast-on/fast-off HDAC binding rate, pimelic diphenylamide 106 progressively binds HDACs and remains bound after wash-out. As a result, the IC50 of pimelic diphenylamide 106 decreases over time. With prolonged preincubation (1-3 hours), pimelic diphenylamide inhibits the class I HDACs (IC50 = 150, 760, 370, and 5,000 nM for HDAC1, 2, 3, and 8, respectively) but not the class II HDACs (IC50 > 180 μM for HDAC4, 5, and 7). Pimelic diphenylamide 106 and related benzamide HDAC inhibitors may have therapeutic value in Friedrich’s ataxia and Huntington’s disease, in part due to their low animal toxicity. | [Uses]
TC-H 106 is a slow, tight-binding inhibitor of class I histone deacetylases. | [Definition]
ChEBI: N'-(2-aminophenyl)-N-(4-methylphenyl)heptanediamide is an aromatic amine and an aromatic amide. | [General Description]
A cell-permeable p-tolylbenzamide and a Histone Deacetylase (HDAC) Inhibitor IV (Cat. No. 382170) analog that acts as a selective inhibitor against class I HDAC1,2,3 (IC50 = 0.15, 0.76, and 0.37 μM with 15, 30, and 180 min preincubation, respectively), while exhibiting much lower acitivity against class I HDAC8 (IC50 ≥ 5μM with 3 h preincubation) and no activity against class II HDAC4/5/7 even at concentrations as high as 180μM. Although the mode of inhibition is mechanistically competitive and reversible, due to the slow- and tight-binding nature, long preincubation is often required for effective in vitro enzyme inhibition, while 106-induced cellular H3 hyperacetylation is shown to persist for more than 6 hours after inhibitor removal by washing in GM15850 culture. 106 is reported to be less cytotoxic than TSA (Cat. No. 647925), MS-275, and SAHA (EC50 = 6.3, 0.328, 0.768, and 1.5 μM, respectively, in GM15850 killing). | [Biochem/physiol Actions]
Pimelic diphenylamides has the ability to enhance the expression of the frataxin gene in lymphocytes from Friedreich ataxia patients. | [storage]
-20°C | [References]
[1]. chou cj, herman d, gottesfeld jm. pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class i histone deacetylases. j biol chem, 2008, 283(51): 35402-35409.
[2]. xu c, soragni e, chou cj, et al. chemical probes identify a role for histone deacetylase 3 in friedreich's ataxia gene silencing. chem biol, 2009, 16(9): 980-989.
[3]. rai m, soragni e, jenssen k, et al. hdac inhibitors correct frataxin deficiency in a friedreich ataxia mouse model. plos one, 2008, 3(4): e1958. |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|